JP2012525358A5 - - Google Patents

Download PDF

Info

Publication number
JP2012525358A5
JP2012525358A5 JP2012507765A JP2012507765A JP2012525358A5 JP 2012525358 A5 JP2012525358 A5 JP 2012525358A5 JP 2012507765 A JP2012507765 A JP 2012507765A JP 2012507765 A JP2012507765 A JP 2012507765A JP 2012525358 A5 JP2012525358 A5 JP 2012525358A5
Authority
JP
Japan
Prior art keywords
treatment
medicament
allopurinol
induced
hfsr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012507765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525358A (ja
JP6007101B2 (ja
Filing date
Publication date
Priority claimed from EP09382058A external-priority patent/EP2246057A1/en
Application filed filed Critical
Publication of JP2012525358A publication Critical patent/JP2012525358A/ja
Publication of JP2012525358A5 publication Critical patent/JP2012525358A5/ja
Application granted granted Critical
Publication of JP6007101B2 publication Critical patent/JP6007101B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012507765A 2009-04-29 2010-04-29 手足皮膚反応治療のためのアロプリノールの使用 Expired - Fee Related JP6007101B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21489409P 2009-04-29 2009-04-29
US61/214,894 2009-04-29
EP09382058A EP2246057A1 (en) 2009-04-29 2009-04-29 Use of allopurinol for the treatment of hand foot skin reaction
EP09382058.7 2009-04-29
PCT/EP2010/055806 WO2010125143A1 (en) 2009-04-29 2010-04-29 Use of allopurinol for the treatment of hand foot skin reaction

Publications (3)

Publication Number Publication Date
JP2012525358A JP2012525358A (ja) 2012-10-22
JP2012525358A5 true JP2012525358A5 (enExample) 2014-12-11
JP6007101B2 JP6007101B2 (ja) 2016-10-12

Family

ID=40897536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012507765A Expired - Fee Related JP6007101B2 (ja) 2009-04-29 2010-04-29 手足皮膚反応治療のためのアロプリノールの使用

Country Status (22)

Country Link
US (2) US8623878B2 (enExample)
EP (2) EP2246057A1 (enExample)
JP (1) JP6007101B2 (enExample)
KR (1) KR20120049848A (enExample)
CN (1) CN102421436B (enExample)
AR (1) AR076505A1 (enExample)
AU (2) AU2010243594A1 (enExample)
BR (1) BRPI1011971A2 (enExample)
CA (1) CA2759085C (enExample)
DK (1) DK2424538T3 (enExample)
ES (1) ES2434366T3 (enExample)
HR (1) HRP20131070T1 (enExample)
IL (1) IL215831A (enExample)
ME (1) ME01567B (enExample)
MX (1) MX2011011529A (enExample)
NZ (1) NZ595901A (enExample)
PL (1) PL2424538T3 (enExample)
PT (1) PT2424538E (enExample)
RS (1) RS53005B (enExample)
RU (1) RU2543325C2 (enExample)
SI (1) SI2424538T1 (enExample)
WO (1) WO2010125143A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508295A (ja) 2009-10-16 2013-03-07 デューク・ユニヴァーシティ 薬物誘発性手足症候群を治療するための組成物および方法
US20140031310A1 (en) * 2011-01-18 2014-01-30 John Maki Pharmaceutical compositions and methods for making and using them
CN111601617A (zh) 2017-12-13 2020-08-28 上海岸阔医药科技有限公司 一种用于预防或治疗与egfr 被抑制相关疾病的方法
JP7520366B2 (ja) * 2018-04-16 2024-07-23 オンクオリティー ファーマシューティカルズ チャイナ リミテッド 腫瘍療法の副作用の予防または治療方法
US20200046703A1 (en) * 2018-08-09 2020-02-13 Asymmetric Therapeutics, Llc Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents
JP2025502006A (ja) 2022-01-05 2025-01-24 アシンメトリック セラピューティクス,エルエルシー 皮膚の増殖性疾患及び他の皮膚症状を治療するための方法及び組成物
KR20250056445A (ko) * 2023-10-19 2025-04-28 (주) 수파드엘릭사 수족증후군 또는 수족피부반응의 예방 또는 치료용 약학 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0278040B1 (de) 1987-02-13 1991-08-14 Pharm-Allergan Gmbh Verwendung von Pteridinen und/oder Purinen oder eines Xanthinoxidase-Hemmers zur Herstellung eines Arzneimittels zur Behandlung von genetisch bedingten degenerativen Netzhauterkrankungen
WO1994005293A1 (en) 1992-09-04 1994-03-17 Aws Shakir Mustafa Salim Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
GB9218711D0 (en) 1992-09-04 1992-10-21 Salim Aws S M Skin cancer treatment
JP3106817B2 (ja) 1993-11-02 2000-11-06 富士電機株式会社 漏電遮断器
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6060083A (en) 1999-04-01 2000-05-09 Topical Technologies, Inc. Topical DMSO treatment for palmar-plantar erythrodysethesia
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
EP1343492B1 (en) 2000-11-22 2006-02-01 Rxkinetix, Inc. Treatment of mucositis
US7544348B2 (en) 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
DK1455888T3 (da) 2001-08-29 2009-08-24 Pharmakodex Ltd Topisk indgivelsesindretning
CN1596111A (zh) 2001-11-29 2005-03-16 桑得医药品公司 减轻化疗引起的不良效果的组合物及方法
DE10200578A1 (de) 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
US6979688B2 (en) 2002-02-12 2005-12-27 Ford John P Treatment method against side-effects of chemotherapy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CA2528359A1 (en) 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
JP2007501864A (ja) 2003-06-11 2007-02-01 ノバセア インコーポレイティッド 活性ビタミンd化合物単独または他の治療薬との併用による、免疫介在疾患の治療法
US20050148906A1 (en) 2003-12-24 2005-07-07 Gregory Skover Apparatus for treatment of the skin having a signaling marker
JP4405326B2 (ja) 2004-06-28 2010-01-27 株式会社東芝 ランドリー機器
EP1796660B1 (en) 2004-09-17 2016-11-23 BioMAS Ltd. Use of ammonium trichloro(dioxyethylene-o,o')tellurate (as101) for the inhibition of interleukin-1beta-converting enzyme
DE602007004849D1 (de) 2006-06-01 2010-04-01 Nobera Pharma Sl Verwendung von allopurinol zur behandlung von palmarer/plantarer erythrodysästhesie

Similar Documents

Publication Publication Date Title
JP2014515373A5 (enExample)
JP2012525358A5 (enExample)
JP2014516942A5 (enExample)
JP2013516482A5 (enExample)
JP2009102342A5 (enExample)
JP2015528471A5 (enExample)
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
JP2017506624A5 (enExample)
RU2012133969A (ru) Локальные трансдермальные композиции дексмедетомидина и способы их применения
NZ714963A (en) Compositions and methods for treating anemia
RU2008152341A (ru) Применение аллопуринола для лечения ладонно-подошвенной эритродизестезии
JP2013511534A5 (enExample)
JP2002528502A5 (enExample)
JP2017533972A5 (enExample)
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
JP2013541583A5 (enExample)
RU2015102772A (ru) Бензодиазелипы для мелкоклеточного рака легкого
JP2015528501A5 (enExample)
CN105380941A (zh) 苯酞类化合物药物用途及其医药组合物
JP2020500864A5 (enExample)
CA2313270A1 (en) Use of deferiprone in treating and preventing iron-induced cardiac disease
JP2016505050A5 (enExample)
RU2013108390A (ru) Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека
RU2011148355A (ru) Применение аллопуринола для ладонно-родошвенного синдрома
JP2011500589A5 (enExample)